Santiago, Chile

Biosigma S.a.


USPTO Granted Patents = 14

% Expired Patents = 64.3

Forward Citations = 11

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal Ricardo Badilla Ohlbaum (6 out of 6 patents)

silverMedal Pilar A Parada Valdecantos (6 out of 6 patents)

bronzeMedal Pilar Angélica Parada Valdecantos (5 out of 5 patents)

4 Katia Nicole Ehrenfeld Stolzenbach (4 out of 4 patents)

5 Alejandro Eduardo Maass Sepúlveda (4 out of 4 patents)

6 Andrés Octavio Aravena Duarte (4 out of 4 patents)

7 Mauricio Alejandro Gonzalez Canales (3 out of 3 patents)

8 Servet Martinez Aguilera (3 out of 3 patents)

9 Roberto Andres Bobadilla Fazzini (2 out of 2 patents)

10 Patricio Ernesto Martinez Bellange (2 out of 2 patents)

11 Leandro Mauricio Padilla Iglesias (2 out of 2 patents)

12 Pedro Antonio Morales Cerda (2 out of 2 patents)

13 Atsuko Ohata (2 out of 2 patents)

14 Manabu Manabe (2 out of 2 patents)

15 Enrique Anselmo Roman Espinoza (1 out of 2 patents)


14 patents:

BIOSIGMA S.A. is a leading biotechnology company specializing in the development and production of high-quality biological reagents and laboratory diagnostic solutions. With a commitment to scientific excellence and innovation, BIOSIGMA provides a wide range of products for research, clinical diagnostics, and biopharmaceutical manufacturing. Our products are used by scientists, healthcare professionals, and pharmaceutical companies worldwide, enabling advancements in various fields such as genomics, proteomics, and immunology. With a strong focus on customer satisfaction and reliable support, BIOSIGMA continues to deliver cutting-edge solutions that contribute to improving human health and well-being.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

14 Patents

#6 in Santiago

#8 in Chile

#42,111 in the World

Santiago, CL
Santiago, Chile
Forward Citations = 11

26 inventors:

Please report any incorrect information to [email protected]
Loading…